Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "All combinations of three factors (inoculation with Salmonella choleraesuis on Day 0, PRRSV on Day 3, and treatment with dexamethasone on Days 3–7) were used to produce eight treatment groups in two independent trials." provenance.
- SENTENCE label "All combinations of three factors (inoculation with Salmonella choleraesuis on Day 0, PRRSV on Day 3, and treatment with dexamethasone on Days 3–7) were used to produce eight treatment groups in two independent trials." provenance.
- SENTENCE label "All combinations of three factors (inoculation with Salmonella choleraesuis on Day 0, PRRSV on Day 3, and treatment with dexamethasone on Days 3–7) were used to produce eight treatment groups in two independent trials." provenance.
- SENTENCE label "All combinations of three factors (inoculation with Salmonella choleraesuis on Day 0, PRRSV on Day 3, and treatment with dexamethasone on Days 3–7) were used to produce eight treatment groups in two independent trials." provenance.
- SENTENCE label "All combinations of three factors (inoculation with Salmonella choleraesuis on Day 0, PRRSV on Day 3, and treatment with dexamethasone on Days 3–7) were used to produce eight treatment groups in two independent trials." provenance.
- SENTENCE label "All combinations of three factors (inoculation with Salmonella choleraesuis on Day 0, PRRSV on Day 3, and treatment with dexamethasone on Days 3–7) were used to produce eight treatment groups in two independent trials." provenance.
- SENTENCE label "In this case series, we share we's experience in using dexamethasone in five COVID-19 infected patients with acute respiratory distress syndrome." provenance.
- SENTENCE label "In this case series, we share we's experience in using dexamethasone in five COVID-19 infected patients with acute respiratory distress syndrome." provenance.
- SENTENCE label "In this case series, we share we's experience in using dexamethasone in five COVID-19 infected patients with acute respiratory distress syndrome." provenance.
- SENTENCE label "Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus Lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin) using web-based simple (unstratified) randomisation with allocation concealment." provenance.
- SENTENCE label "Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus Lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin) using web-based simple (unstratified) randomisation with allocation concealment." provenance.
- SENTENCE label "Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus Lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin) using web-based simple (unstratified) randomisation with allocation concealment." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF)-α)-induced gene/protein 6 (TSG)-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for Canine inflammatory bowel disease (IBD) treatment in veterinary medicine." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that Interferon-α (IFN)-α) and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that Interferon-α (IFN)-α) and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that Interferon-α (IFN)-α) and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "Repurposed anti-viral drugs have played a huge role in combating the virus, and most recently, dexamethasone (Dex) have shown dexamethasone (Dex)'s therapeutic activity in severe cases of COVID-19 patients." provenance.
- SENTENCE label "Repurposed anti-viral drugs have played a huge role in combating the virus, and most recently, dexamethasone (Dex) have shown dexamethasone (Dex)'s therapeutic activity in severe cases of COVID-19 patients." provenance.
- SENTENCE label "Repurposed anti-viral drugs have played a huge role in combating the virus, and most recently, dexamethasone (Dex) have shown dexamethasone (Dex)'s therapeutic activity in severe cases of COVID-19 patients." provenance.
- SENTENCE label "Repurposed anti-viral drugs have played a huge role in combating the virus, and most recently, dexamethasone (Dex) have shown dexamethasone (Dex)'s therapeutic activity in severe cases of COVID-19 patients." provenance.
- SENTENCE label "Repurposed anti-viral drugs have played a huge role in combating the virus, and most recently, dexamethasone (Dex) have shown dexamethasone (Dex)'s therapeutic activity in severe cases of COVID-19 patients." provenance.
- SENTENCE label "Repurposed anti-viral drugs have played a huge role in combating the virus, and most recently, dexamethasone (Dex) have shown dexamethasone (Dex)'s therapeutic activity in severe cases of COVID-19 patients." provenance.
- SENTENCE label "A total of 18 patients (36%) showed an increase of A total of 18 patients (36%)'s cortisol levels after dexamethasone administration and 32 patients (64%) showed a decrease." provenance.
- SENTENCE label "A total of 18 patients (36%) showed an increase of A total of 18 patients (36%)'s cortisol levels after dexamethasone administration and 32 patients (64%) showed a decrease." provenance.
- SENTENCE label "A total of 18 patients (36%) showed an increase of A total of 18 patients (36%)'s cortisol levels after dexamethasone administration and 32 patients (64%) showed a decrease." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021–0.36]; P < 0.001)." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "prenatal dexamethasone (DEX) exposure suppressed plasma angiotensin (ANG) I and ANG II, whereas postnatal HF suppressed plasma ANG-(1–7) level." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.
- SENTENCE label "Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery." provenance.